Boston Scientific Long-Term Debt and Lease Obligation increased by 0.2% to $11.14B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 24.2%, from $8.97B to $11.14B. Over 5 years (FY 2020 to FY 2025), Long-Term Debt and Lease Obligation shows an upward trend with a 4.1% CAGR.
High levels indicate significant leverage, which can amplify returns but also increase financial risk during economic downturns.
This represents the principal amount of debt and lease obligations that are due beyond the next twelve months. It reflec...
Standard across all capital-intensive industries; compared against EBITDA to determine debt-to-EBITDA leverage ratios.
other_long_term_debt_and_capital_lease_obligations| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.85B | $8.82B | $8.80B | $9.07B | $8.80B | $8.56B | $8.92B | $8.50B | $8.49B | $8.39B | $8.57B | $9.53B | $8.99B | $9.23B | $8.97B | $10.53B | $11.11B | $11.12B | $11.14B |
| QoQ Change | — | -0.3% | -0.2% | +3.0% | -2.9% | -2.7% | +4.1% | -4.7% | -0.0% | -1.3% | +2.2% | +11.2% | -5.7% | +2.7% | -2.9% | +17.4% | +5.5% | +0.1% | +0.2% |
| YoY Change | — | — | — | — | -0.5% | -2.9% | +1.3% | -6.3% | -3.5% | -2.1% | -3.9% | +12.2% | +5.9% | +10.1% | +4.6% | +10.5% | +23.5% | +20.4% | +24.2% |